胰高血糖素样肽-1受体激动剂使用与食管动力异常相关并可能致病
本研究旨在评估GLP-1RA暴露与食管高分辨率测压(HRM)表现的相关性。GLP-1RA已知影响胃肠动力,但对食管功能直接影响了解甚少。该研究可能发现GLP-1RA使用与食管动力异常相关。
要点
- GLP-1RA使用可能与食管动力异常相关。
- GLP-1RA对食管功能的影响超出已知的GERD风险。
- 需进一步研究明确因果关系。
核心结论
- GLP-1RA使用与食管动力异常相关,并可能致病。
研究设计与样本
- 评估GLP-1RA暴露与食管高分辨率测压(HRM)表现相关性的研究。
主要发现
- GLP-1RA使用与食管动力异常相关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are approved for the treatment of obesity and type 2 diabetes mellitus (T2D). GLP1-RA use has grown exponentially, with a recent survey reporting 1 in 8 adults (12%) in the United States have ever taken a GLP-1RA.1 GLP-1RAs are known to cause a variety of effects on gastrointestinal motility, including increased gastric accommodation, delayed gastric motility, and decreased small intestinal transit. However, little is known regarding the direct effects of GLP-1RAs on esophageal function beyond reported increased risk of gastroesophageal reflux disease (GERD).2 The primary aim of this study was to assess the association of GLP-1RA exposure with findings on esophageal high-resolution manometry (HRM).
引用
- Gala K, Camilleri M, Goyal M, et al. Glucagon-Like Peptide-1 Receptor Agonist Use Is Associated With and May Lead to Esophageal Motility Abnormalities. Clin Gastroenterol Hepatol. 2025. PMID: 41213390. doi:10.1016/j.cgh.2025.11.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。